Likewise, one study found that intrathecal fingolimod reduces bone cancer pain (Grenald et al., 2017), and while analgesia was attributed to effects on S1PR1 in glia, some of the benefits may be due to S1PR3 signaling in DRG neurons. This evidence concerns the gene S1PR3 and bone neoplasm.